Richard L. Monaghan

4.6k total citations · 2 hit papers
36 papers, 3.6k citations indexed

About

Richard L. Monaghan is a scholar working on Molecular Biology, Pharmacology and Biotechnology. According to data from OpenAlex, Richard L. Monaghan has authored 36 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Pharmacology and 8 papers in Biotechnology. Recurrent topics in Richard L. Monaghan's work include Microbial Natural Products and Biosynthesis (14 papers), Fungal Biology and Applications (6 papers) and Microbial Metabolism and Applications (5 papers). Richard L. Monaghan is often cited by papers focused on Microbial Natural Products and Biosynthesis (14 papers), Fungal Biology and Applications (6 papers) and Microbial Metabolism and Applications (5 papers). Richard L. Monaghan collaborates with scholars based in United States, Japan and Spain. Richard L. Monaghan's co-authors include E. O. Stapley, Otto D. Hensens, G. Albers‐Schönberg, Jerrold M. Liesch, H Joshua, V. M. Hunt, John W. Rothrock, Jesse W. Huff, J. HIRSHFIELD and E. J. Harris and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Richard L. Monaghan

36 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.

1980 1.3k citations Richard L. Monaghan, E. O. Stapley et al. profile →
Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation

1979 728 citations Richard W. Burg, Sara Currie et al. profile →

Peers

Countries citing papers authored by Richard L. Monaghan

Since Specialization

Citations

This map shows the geographic impact of Richard L. Monaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard L. Monaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard L. Monaghan more than expected).

Fields of papers citing papers by Richard L. Monaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard L. Monaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard L. Monaghan. The network helps show where Richard L. Monaghan may publish in the future.

Co-authorship network of co-authors of Richard L. Monaghan

This figure shows the co-authorship network connecting the top 25 collaborators of Richard L. Monaghan. A scholar is included among the top collaborators of Richard L. Monaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard L. Monaghan. Richard L. Monaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antibacterial drug discovery—Then, now and the genomics future 2006 ·Biochemical Pharmacology ·Richard L. Monaghan, John F. Barrett	74
2	Microbial transformation ofN-heptyl physostigmine, a semisynthetic alkaloid inhibitor of cholinesterase 1995 ·Journal of Industrial Microbiology & Biotechnology ·(unknown), Rebecca B. White, Byron H. Arison, (unknown), Michael S. Schwartz, Hsien C. Cheng, Richard L. Monaghan, (unknown)	4
3	Microbial transformations of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin(immunomycin) by Streptomyces sp. MA6970(ATCC No.55281). 1994 ·The Journal of Antibiotics ·(unknown), (unknown), Richard White, Gabe Dezeny, (unknown), Byron H. Arison, T. R. BEATTIE, (unknown), Francis J. Dumont, Richard L. Monaghan	2
4	Microbial transformation of immunosuppressive compounds III. Glucosylation of immunomycin (FR 900520) and FK 506 byBacillus subtilis ATCC 55060 1994 ·Journal of Industrial Microbiology & Biotechnology ·(unknown), Byron Arison, (unknown), Richard L. Monaghan, Francis J. Dumont, (unknown)	5
5	The preparation of zaragozic acid A analogues by directed biosynthesis. 1994 ·The Journal of Antibiotics ·(unknown), (unknown), John G. MacConnell, R. F. White, Gabe Dezeny, Byron Arison, James D. Bergstrom, (unknown), Liang Huang, Richard L. Monaghan	18
6	Microbial Transformation of L-696, 474, a Novel Cytochalasin as an Inhibitor of HIV-1 Protease 1993 ·Journal of Natural Products ·(unknown), George A. Doss, (unknown), Amy Hsu, Russell B. Lingham, Raymond F. White, Richard L. Monaghan	13
7	Improvement in the titer of echinocandin-type antibiotics: A magnesium-limited medium supporting the biphasic production of pneumocandins A0 and B0 1993 ·Journal of Industrial Microbiology & Biotechnology ·Jan S. Tkacz, R.A. Giacobbe, Richard L. Monaghan	31
8	Microbial hydroxylation and glucuronidation of the angiotensin II(A II) receptor antagonist MK 954. 1993 ·The Journal of Antibiotics ·(unknown), (unknown), Rebecca B. White, Richard L. Monaghan	13
9	L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. I. The producing organism and its fermentation. 1992 ·The Journal of Antibiotics ·Anne W. Dombrowski, Gerald F. Bills, (unknown), Lawrence R. Koupal, Richard F. Meyer, John G. Ondeyka, R.A. Giacobbe, Richard L. Monaghan, Russell B. Lingham	42
10	Sphingofungins A,B,C, and d; a new family of antifungal agents. I. Fermentation, isolation, and biological activity. 1992 ·The Journal of Antibiotics ·Frank VanMiddlesworth, R.A. Giacobbe, (unknown), George M Garrity, Judith A. Bland, Ken Bartizal, Robert A. Fromtling, Jon D. Polishook, Marcia Zweerink, (unknown), (unknown), Kenneth E. Wilson, Richard L. Monaghan	80
11	A NOVEL INOSITOL MONO-PHOSPHATASE INHIBITOR FROM Memnoniella echinata 1992 ·The Journal of Antibiotics ·(unknown), C. F. WICHMANN, M. Meinz, (unknown), R.A. Giacobbe, S. Mochales, (unknown), (unknown), Deborah L. Zink, Gerald F. Bills, Leeyuan Huang, Richard W. Burg, Richard L. Monaghan, Rod Jackson, Gillian Reid, Janet J. Maguire, A.T. McKnight, C I Ragan	27
12	Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK 506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. 1992 ·The Journal of Antibiotics ·(unknown), Byron H. Arison, Linda S. Wicker, Edward Inamine, Richard L. Monaghan	21
13	L-671,329, a new antifungal agent. I. Fermentation and isolation. 1989 ·The Journal of Antibiotics ·Robert E. Schwartz, R.A. Giacobbe, Judith A. Bland, Richard L. Monaghan	77
14	L-681,572-a new antifungal agent. Isolation, characterization, and biological activity. 1989 ·The Journal of Antibiotics ·Louis Chaiet, Robert A. Fromtling, George M Garrity, Richard L. Monaghan, Otto D. Hensens, (unknown), Deborah L. Zink	3
15	L-657,398, a novel antifungal agent: Fermentation, isolation, structural elucidation and biological properties. 1988 ·The Journal of Antibiotics ·Robert E. Schwartz, Jerrold M. Liesch, Otto D. Hensens, LAURETTA ZITANO, (unknown), George M Garrity, Robert A. Fromtling, Janet C. Onishi, Richard L. Monaghan	91
16	Novel cholecystokinin antagonists from Aspergillus alliaceus. I. Fermentation, isolation, and biological properties. 1988 ·The Journal of Antibiotics ·Michael Goetz, Richard L. Monaghan, Raymond S.L. Chang, John G. Ondeyka, (unknown), Victor J. Lotti	30
17	Difficidin and oxydifficidin: Novel broad spectrum antibacterial antibiotics produced by Bacillus subtilis. I.Production, taxonomy and antibacterial activity. 1987 ·The Journal of Antibiotics ·S. B. Zimmerman, Cheryl D. Schwartz, Richard L. Monaghan, Barbara A. Pelak, (unknown), (unknown), S. Mochales, Sebastian Hernandez, Sara Currie, (unknown), E. O. Stapley	79
18	L-681,217, a new and novel member of the efrotomycin family of antibiotics. 1986 ·The Journal of Antibiotics ·AUGUST J. KEMPF, Kenneth E. Wilson, Otto D. Hensens, Richard L. Monaghan, S. B. Zimmerman, Eugene L. Dulaney	17
19	Functions of extracellular lysine residues in the human erythrocyte anion transport protein. 1985 ·The Journal of General Physiology ·Michael L. Jennings, Richard L. Monaghan, (unknown), (unknown)	34
20	Dihydrocompactin,a new potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase from Penicillium citrinum. 1981 ·The Journal of Antibiotics ·(unknown), Vincent P. Gullo, Robert T. Goegelman, (unknown), Leeyuan Huang, (unknown), Richard L. Monaghan, Irving Putter	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact